Supramolecular glycodendrimer-based hybrid drugs

Area of Science:

• Supramolecular Chemistry
• Medicinal Chemistry
• Biotechnology

Background:

• Nature utilizes specific noncovalent interactions for critical biological processes like cell recognition and viral adhesion.
• Developing novel drug delivery systems and therapeutic agents relies on understanding and mimicking these natural interactions.

Purpose of the Study:

• To design, synthesize, and characterize new supramolecular glycodendrimer-based hybrid drugs.
• To create constructs capable of targeting specific biological receptors through noncovalent binding.

Main Methods:

• Synthesis of adamantyl-modified glycodendrimers of varying generations (G3, G4, G5).
• Design of a heterobifunctional ligand with an arylpiperazine pharmacophore and a β-cyclodextrin residue.
• Characterization of the resulting supramolecular hybrid drug constructs.

Main Results:

• Successful synthesis of adamantyl-modified glycodendrimers (mPPI-G3-AdaB, mPPI-G4-AdaB, mPPI-G5-AdaB).
• Creation of a heterobifunctional ligand capable of binding both the 5-HT3 receptor and the glycodendrimer's adamantyl groups.
• Formation of biorelevant supramolecular constructs through noncovalent interactions.

Conclusions:

• The developed supramolecular constructs demonstrate a novel approach for hybrid drug design.
• These glycodendrimer-based systems show potential for targeted drug delivery and therapeutic modulation of receptors like 5-HT3.